Immunocore (NASDAQ:IMCR) Sets New 12-Month Low – Here’s Why

Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR – Get Free Report)’s share price reached a new 52-week low during mid-day trading on Tuesday. The stock traded as low as $27.31 and last traded at $27.74, with a volume of 259,620 shares traded. The stock had previously closed at $28.88.

Analyst Ratings Changes

A number of research analysts recently commented on the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of Immunocore in a report on Thursday, October 15th. HC Wainwright decreased their price target on Immunocore from $100.00 to $80.00 and set a “buy” rating for the company in a report on Tuesday, November 10th. TD Cowen raised Immunocore to a “strong-buy” rating in a research report on Monday, August 24th. Wall Street Zen cut Immunocore from a “buy” rating to a “hold” rating in a research report on Tuesday, July 28th. Finally, Zacks Research cut Immunocore from a “hold” rating to a “strong sell” rating in a research report on Monday, November 9th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, three have issued a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $52.86.

View Our Latest Report on IMCR

Immunocore Trading Down 3.7%

The firm has a market cap of $1.43 billion, a price-to-earnings ratio of -42.78 and a beta of 0.82. The company has a debt-to-equity ratio of 0.94, a quick ratio of 4.44 and a current ratio of 4.62. The business has a fifty day moving average of $30.92 and a two-hundred day moving average of $31.61.

Immunocore (NASDAQ:IMCR – Get Free Report) last issued its quarterly earnings data on Friday, November 6th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by ($0.11). The firm had revenue of $102.22 million for the quarter, compared to analyst estimates of $152.09 million. Immunocore had a negative return on equity of 7.96% and a negative net margin of 7.48%. As a group, equities analysts expect that Immunocore Holdings PLC Sponsored ADR will post -0.20 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. Braidwell LP acquired a new stake in Immunocore in the 2nd quarter worth about $16,552,000. Janus Henderson Group PLC grew its holdings in Immunocore by 30.9% in the 1st quarter. Janus Henderson Group PLC now owns 594,712 shares of the company’s stock valued at $17,919,000 after buying an additional 140,308 shares during the period. Public Employees Retirement System of Ohio purchased a new stake in Immunocore in the 2nd quarter valued at about $2,145,000. Stempoint Capital LP acquired a new position in shares of Immunocore during the 1st quarter valued at about $1,916,000. Finally, Engineers Gate Manager LP increased its stake in shares of Immunocore by 334.3% during the 2nd quarter. Engineers Gate Manager LP now owns 60,327 shares of the company’s stock valued at $1,915,000 after acquiring an additional 46,435 shares during the last quarter. Hedge funds and other institutional investors own 84.50% of the company’s stock.

About Immunocore

(Get Free Report)

Immunocore is a biotechnology company that develops T cell receptor (TCR)-based medicines for cancer and other diseases. Its ImmTAX platform is designed to create therapies that direct the body’s T cells toward targets inside cells, including targets that may be difficult for conventional antibody treatments to reach. The company’s marketed medicine, KIMMTRAK (tebentafusp-tebn), is a TCR-based therapy approved in the United States and other markets for certain patients with unresectable or metastatic uveal melanoma.

Recommended Stories

Receive News & Ratings for Immunocore Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunocore and related companies with MarketBeat.com's FREE daily email newsletter.